

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO-1449 (modified)				Atty. Docket #		Serial No.	
				2003.793 US		Unassigned	
				Applicant Jeroen A. D. M. TONNAER			
				Filing Date Even Date Herewith		Group Art Unit Unassigned	
U.S. PATENT DOCUMENTS							
Init	Document Number	Date	Name	Class	Subclass	Filing Date	
	5,763,476	06-1998	Delbressine et al.	514	410		
	2002/0156067 A1	10-2002	Wong et al.	514	220		
FOREIGN PATENT DOCUMENTS							
	Document Number	Publ. Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 95/23600 A1	09-1995	PCT International	A61K	31/40		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) continued on page 2							
	International Search Report No. PCT/EP2004/051069 dated November 29, 2004.						
	Miguel-Hidalgo, J.J., "Org-5222 NV Organon," Current Opinion in CPNS Investigational Drugs, Pharma Press, London, GB, Vol. 2, No. 1, 2000, pp. 85-92.						
	"Org-5222; Antipsychotic, Dopamine D ₂ Receptor Antagonist, 5-HT ₂ Receptor Antagonist," Drugs of the Future, Barcelona, ES, Vol. 18, No. 12, 1993, pp. 1117-1123.						
	Sartorius, N. et al., "The Usefulness and Use of Second-Generation Antipsychotic Medications: Preface," Current Opinion in Psychiatry, United Kingdom, Vol. 15, Suppl. 1, 2002, pp. S1-S51.						
	McIntyre, R. S. et al., "Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities," Canadian Journal of Psychiatry, Vol. 46, No. 3, 2001, pp. 273-281.						
	Sussman, N., "Review of Atypical Antipsychotics and Weight Gain," The Journal of Clinical Psychiatry, U.S., Vol. 62, Suppl. 23, 2001, pp. 5-12.						
	Russell, J. M. et al., "Bodyweight Gain Associated with Atypical Antipsychotics: Epidemiology and Therapeutic Implications," CNS Drugs, New Zealand, Vol. 15, No. 7, 2001, pp. 537-551.						
	Blin, O. et al., "Antipsychotic-Associated Weight Gain and Clinical Outcome Parameters," The Journal of Clinical Psychiatry, U.S., Vol. 62, Suppl. 7, 2001, pp. 11-21.						
	Malhotra, S. et al., "Medical Management of Obesity Associated with Mental Disorders," The Journal of Clinical Psychiatry, U.S., Vol. 63, Suppl. 4, 2002, pp. 24-32.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/